SYRS News and Press, Syros Pharmaceuticals Inc. From 09/15/22

-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” -- -- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and ...

Syros Pharmaceuticals ( NASDAQ: SYRS ) on Tuesday said the U.S. FDA had granted an orphan drug designation to its inhibitor SY-5609 for the treatment of pancreatic cancer. SY-5609 is currently being assessed in combination with chemotherapy for the treatment of patients wi...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SY-5609 for the treatment of pancreatic cancer. SY-5609...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday! News moving stocks this morning include clinical trial updates, earnings reports...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference. ...

Shares of Syros Pharmaceuticals ( NASDAQ: SYRS ) lost as much as 12.8% to $0.85 in Tuesday afternoon trading, after the company reported a mixed set of Q2 numbers and announced preliminary data from a dose-confirmation trial. It is worth noting that SYRS stock gained 1...

Syros Pharmaceuticals, Inc. (SYRS) Q2 2022 Earnings Conference Call August 09, 2022 08:30 AM ET Company Participants Courtney Solberg - Manager of Corporate Communications & Investor Relations Nancy Simonian - Chief Executive Officer David Roth - Chief Medica...

Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q2 GAAP EPS of -$0.54 misses by $0.13 . Revenue of $6.28M (+21.7% Y/Y) beats by $1.5M . Cash and Financial Guidance Cash, cash equivalents and marketable securities as of June 30, 2022 were $86.3 milli...

Preliminary Data From First Cross-Over Study Directly Comparing PK of SY-2101 to the Approved IV Dose of ATO Demonstrates Comparable PK Exposures; Expect to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Definitive Merger Agreement with TYME Technologies and Concurr...

Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.41 (-13.9% Y/Y) and the consensus Revenue Estimate is $4.78M (-7.4% Y/Y). Over the last 1 year, SYRS has ...